Liquidia Technologies, Inc.
11
3
5
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
9.1%
1 terminated/withdrawn out of 11 trials
75.0%
-11.6% vs industry average
45%
5 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
Role: lead
A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks
Role: lead
The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease
Role: collaborator
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
Role: lead
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Role: lead
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
Role: lead
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
Role: lead
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
Role: lead
Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
Role: lead
Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations
Role: lead
A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001
Role: lead
All 11 trials loaded